Distribution and anti-HBV effects of antisense oligodeoxynu-cleotides conjugated to galactosylated poly-L-lysine

Figure 1 Amplification of HBV DNA in the 2. 2.15 cells with PCR. The PCR products were resolved on 1.5% agarose gel. M: Molecule weight marker; A: HBV DNA in 2.2.15 cells.

Figure 2 Analysis of Gal-PLL/asODNs complex formation at different molar ratios. A: Gal-PLL/asODNs = 3:1; B: Gal-PLL/asODNs = 2:1; C: Gal-PLL/asODNs = 1.75:1; D: Gal-PLL/asODNs = 1.5:1; E: Gal-PLL/asODNs = 1:1; F: Gal-PLL/asODNs = 0. 5:1; G: Gal-PLL/asODNs = 0:1.

Figure 3 Distribution of asODNs in Kunming mice (n = 2).

Figure 4 Distribution of Gal-PLL-asODNs in Kunming mice (n = 2).

Figure 5 Comparision of the amount retained in liver between asODNs and Gal-PLL-asODNs (n = 2).

Figure 6 Products of HBV DNA nested-PCR in the mice serum after 12 d treatment. Lane A: Products of HBVDNA nested-PCR in serum after normal saline treatment; Lane B: Products of HBVDNA nested-PCR in serum after asODNs treatment. M: Molecule weight marker.